Physician profile
Randee D Willis
NPI 1073618260
$3,884.69
in general payments reported to CMS, 2019-2025
25 companies · $666 in 2025
The $666 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $745 · 2022: $1,115 · 2023: $726 · 2024: $633 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,832 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,831.76 |
| Education | $193.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $595.38 | 2021-2025 | |
| Janssen Biotech, INC. | $589.20 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Galderma Laboratories, L.P. | $475.89 | 2021-2025 | |
| Genzyme Corporation | $324.49 | 2021-2025 | |
| Pfizer INC. | $286.98 | 2021-2025 | |
| Botanix Sb INC | $269.93 | 2025 | Sofdra |
| Incyte Corporation | $193.00 | 2021-2022 | |
| Lilly USA, LLC | $154.60 | 2021-2023 | Taltz, Olumiant |
| Arcutis Biotherapeutics, INC. | $152.18 | 2023 | |
| Amgen INC. | $128.89 | 2023-2024 | Otezla |
| Biofrontera INC. | $109.48 | 2022-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Ucb, INC. | $93.87 | 2022-2025 | Bimzelx |
| Genentech USA, INC. | $72.73 | 2022 | |
| Mayne Pharma Commercial LLC | $65.63 | 2023-2024 | |
| Janssen Scientific Affairs, LLC | $60.00 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $56.02 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.16 | 2022-2023 | Spevigo |
| Novartis Pharmaceuticals Corporation | $40.40 | 2022-2024 | |
| Almirall LLC | $40.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $24.60 | 2024 | Sotyktu |
| Lnhc, INC | $23.92 | 2025 | Zelsuvmi |
| Regeneron Healthcare Solutions, INC. | $23.05 | 2025 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.00 | 2021 | |
| Dermavant Sciences, INC. | $19.42 | 2023 | Vtama |
| Journey Medical Corporation | $12.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randee Willis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.